⌘K
t
On 4 March 2026, EDX Medical Group PLC announced that a warrant holder exercised warrants issued at an exercise price of 10p per ordinary share. Following this exercise, the company has 411,844,583 ordinary shares in issue, with admission of the newly issued shares to the Aquis Stock Exchange expected on 10 March 2026.
| Date | 4 Mar 2026 |
| Time | 16:05:00 |
| Category | Miscellaneous |
| ID | 3677V |
4 March 2026
("EDX Medical" or the "Company")
Exercise of Warrants
CAMBRIDGE, UK: EDX Medical Group plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, announces that a warrant holder has agreed to exercise their warrants over ordinary shares in EDX Medical, in accordance with the terms of the warrant instrument.
The warrants were issued at an exercise price of 10p per ordinary share to the first warrant holders of TECC Capital plc ("TECC"). EDX Medical Ltd was acquired by TECC via a reverse takeover in 2022, upon which TECC then changed its name to EDX Medical Group plc.
The Company has a remaining 12,100,000 warrants in place with an exercise price of 10p per ordinary share and 12,500,000 with an exercise price of 20p per ordinary share.
Application will be made for the newly issued shares to be admitted to trading on the Aquis Stock Exchange and it is expected that admission will occur on 10 March 2026.
Following this warrant exercise, the Company has 411,844,583 ordinary shares in issue, each share carrying the right to one vote. This figure serves as the denominator for shareholders to calculate their notification requirements under the Financial Conduct Authority's Disclosure and Transparency Rules regarding their interests in the company's share capital.
The directors of EDX Medical accept responsibility for the contents of this announcement.
ENDS
Contacts:
|
EDX Medical Group plc |
|
|
Dr Mike Hudson (Chief Executive Officer)
|
+44 (0)7812 345 301
|
|
Oberon Capital |
|
|
Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking)
|
+44 (0)20 3179 5300 |
|
Media House International |
|
|
Ramsay Smith
Gary McQueen |
+44 (0)7788 414856
+44 (0)7834 694609
|
|
IFC Advisory (Investor Relations) |
|
|
Tim Metcalfe Graham Herring |
+44 (0) 203 934 6630 |
Notes to Editors:
About EDX Medical Group plc
EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.
EDX Medical provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.